1,436
Participants
Start Date
March 31, 2026
Primary Completion Date
April 30, 2029
Study Completion Date
May 31, 2030
Xenon
50% xenon by inhalation, delivered by customized xenon delivery system, that includes a ventilator, for the 24h period of TH/TTM. The inhalation therapy is provided in combination with protocol-directed Post-Cardiac Arrest Care dictated by the 2015 guidelines from the American Heart Association and the European Resuscitation Council.
University at Buffalo, Buffalo
University of Florida, Gainesville
Baptist Memorial Hospital, Baptist Clinical Research Institute, Memphis
Memorial Hospital at Gulfport, Gulfport
Wexner Medical Center, Ohio State University, Columbus
University Nebraska Medical Center, Omaha
Houston Methodist Research Institute, Houston
Hartford Hospital, Hartford
Aalborg University Hospital, Aalborg
University Hospital, Rigshospitalet, Blegdamsvej 9, Copenhagen
Lead Sponsor
Invero Pharma, Inc.
INDUSTRY